Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Deloitte
QuintilesIMS
Mallinckrodt
Chubb
Covington
Farmers Insurance
McKesson
Baxter

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,371,727

« Back to Dashboard

Which drugs does patent 7,371,727 protect, and when does it expire?

Patent 7,371,727 protects LINZESS and is included in one NDA.

This patent has seventy-four patent family members in twenty-four countries.
Summary for Patent: 7,371,727
Title:Methods and compositions for the treatment of gastrointestinal disorders
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Fretzen; Angelika (Somerville, MA), Sun; Li Jing (New York, NY), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee: Microbia, Inc. (Cambridge, MA)
Application Number:10/899,806
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 7,371,727

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,371,727

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,546 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,304,036 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,704,947 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
8,080,526 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,772,188 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,745,409 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
8,110,553 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,371,727

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2246360 ➤ Subscribe
Slovenia 1911763 ➤ Subscribe
Slovenia 1594517 ➤ Subscribe
Singapore 192300 ➤ Subscribe
Singapore 168407 ➤ Subscribe
Singapore 153824 ➤ Subscribe
Russian Federation 2014153593 ➤ Subscribe
Russian Federation 2543350 ➤ Subscribe
Russian Federation 2008147983 ➤ Subscribe
Russian Federation 2433133 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Merck
Novartis
AstraZeneca
US Army
Julphar
Boehringer Ingelheim
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot